<p>Hims  Hers Health（纽约证券交易所代码：HIMS - 获取免费报告）在周二向客户和投资者发布的研究报告中，银行美林的股票分析师将其目标价格从 30.00 美元下调至 28.00 美元。该公司目前对该股票的评级为 “中性”。银行美林的目标价格暗示该股票当前价格有 25.44% 的潜在上涨空间。</p>
<p>获取 <strong>Hims  Hers Health</strong> 的提醒：</p>
<ul>
<li>Hims  Hers 股票在第一季度业绩不佳后暴跌：GLP-1 转型是否足以推动复苏？</li>
</ul>
<p>其他几位股票研究分析师也对 HIMS 发表了评论。摩根士丹利将 Hims  Hers Health 的目标价格从 40.00 美元下调至 21.00 美元，并在 2 月 24 日的研究报告中对该公司给予 “等权重” 评级。BTIG Research 在 5 月 12 日的研究报告中重申了对 Hims  Hers Health 股票的 “中性” 评级。Weiss Ratings 在 5 月 12 日的研究报告中将 Hims  Hers Health 的评级从 “持有（c）” 下调至 “卖出（d）”。花旗集团在 5 月 12 日的研究报告中将 Hims  Hers Health 的目标价格从 24.00 美元上调至 28.00 美元，并给予该股票 “中性” 评级。最后，Leerink Partners 在 3 月 16 日的研究报告中将 Hims  Hers Health 的目标价格从 17.50 美元上调至 25.00 美元，并给予该股票 “市场表现” 评级。四位分析师对该股票给予买入评级，十一位给予持有评级，二位给予卖出评级。根据 MarketBeat.com 的数据，Hims  Hers Health 目前的平均评级为 “持有”，共识目标价格为 29.37 美元。</p>
<p><strong>获取我们关于 Hims  Hers Health 的最新股票报告</strong></p>
<h2>Hims  Hers Health 价格表现</h2>
<ul>
<li>Hims  Hers 财报预览：诺和诺德的转变将 GLP-1 策略置于焦点</li>
</ul>
<p>在周二的交易中，NYSE:HIMS 的股票上涨了 0.03 美元，达到 22.32 美元。该股票交易量为 20,746,443 股，而其平均交易量为 32,920,871 股。该公司的 50 日移动平均价格为 23.92 美元，200 日移动平均价格为 28.60 美元。该公司的市值为 50.9 亿美元，市盈率为-248.40，市盈增长比率为 44.19，贝塔值为 2.43。该公司的流动比率为 1.69，速动比率为 1.56，债务与股本比率为 2.18。Hims  Hers Health 的 12 个月低点为 13.74 美元，12 个月高点为 70.43 美元。</p>
<p>Hims  Hers Health（纽约证券交易所代码：HIMS - 获取免费报告）最后一次公布季度财报是在 5 月 11 日。该公司报告季度每股收益（EPS）为-0.40 美元，低于市场共识预期的 0.04 美元，差距为 0.44 美元。该公司季度收入为 6.081 亿美元，而分析师预期为 6.1684 亿美元。Hims  Hers Health 的股本回报率为 6.10%，净利润率为-0.56%。与去年同期相比，Hims  Hers Health 的收入增长了 3.8%。去年同期，该公司每股收益为 0.20 美元。分析师平均预测 Hims  Hers Health 在当前年度将发布 0.04 美元的每股收益。</p>
<h2>内部人士下注</h2>
<ul>
<li>FDA 最新提案对 Lilly、Novo 和 Hims 的影响</li>
</ul>
<p>在其他消息中，首席财务官 Oluyemi Okupe 于 4 月 16 日星期四出售了 36,922 股公司的股票。股票以平均价格 25.90 美元出售，总交易额为 956,279.80 美元。出售完成后，首席财务官直接持有 281,867 股公司股票，价值 7,300,355.30 美元。此次交易使其持股减少了 11.58%。该交易在向证券交易委员会的备案中披露，相关信息可在此链接查看。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，内部人士 Soleil Boughton 于 4 月 20 日星期一出售了 9,463 股公司的股票。股票以平均价格 30.00 美元出售，总交易额为 283,890.00 美元。出售后，内部人士直接持有 299,368 股公司股票，价值 8,981,040 美元。这代表其持股减少了 3.06%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去 90 天内，内部人士共出售了 204,857 股公司股票，价值 5,285,706 美元。内部人士持有公司股票的比例为 11.76%。</p>
<h2>Hims  Hers Health 的机构交易</h2>
<p>几家机构投资者最近对 HIMS 的持仓进行了调整。Pathway Capital Management LP 在第三季度购买了 Hims  Hers Health 的新头寸，价值约为 6,766,000 美元。Steadview Capital Management LLC 在第三季度将其在 Hims  Hers Health 的持股增加了 80.0%。Steadview Capital Management LLC 目前持有 701,845 股公司股票，价值 39,809,000 美元，此前在该期间内又购买了 311,845 股。Farallon Capital Management LLC 在第三季度将其在 Hims  Hers Health 的持股增加了 30.8%。Farallon Capital Management LLC 目前持有 10,746,852 股公司股票，价值 609,561,000 美元，此前在该期间内又购买了 2,533,271 股。BIT Capital GmbH 在第三季度将其在 Hims  Hers Health 的持股增加了 73.8%。BIT Capital GmbH 目前持有 2,210,384 股公司股票，价值 125,373,000 美元，此前在该期间内又购买了 938,728 股。最后，密歇根州退休系统在第三季度将其在 Hims  Hers Health 的持股增加了 49.2%。密歇根州退休系统目前持有 2,057,700 股公司股票，价值 116,713,000 美元，此前在该期间内又购买了 678,600 股。63.52% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>影响 Hims  Hers Health 的关键故事</h2>
<p>以下是本周影响 Hims  Hers Health 的关键新闻故事：</p>
<ul>
<li>消极情绪：Hims &amp; Hers 宣布并扩大了一项 0.00% 可转换高级票据的私人发行，计划到 2032 年到期，金额从原定的 3 亿美元增至 3.5 亿美元，这引发了对未来稀释和资产负债表的担忧。文章标题</li>
<li>中性情绪：该公司表示，这笔资金将有助于保持财务灵活性，同时资助国际扩张、基础设施和人工智能平台投资，这可能支持长期增长。文章标题</li>
<li>消极情绪：媒体报道还强调了投资者的担忧，即此举可能与计划中的 Eucalyptus 收购和更广泛的增长举措有关，进一步强化了 Hims &amp; Hers 借债融资扩张的观点。文章标题</li>
</ul>
<h2>关于 Hims &amp; Hers Health</h2>
<p>(获取免费报告)</p>
<p>Hims &amp; Hers Health, Inc 是一个远程医疗平台，提供直接面向消费者的个人护理产品和虚拟医疗服务，服务于美国市场。该公司以 Hims &amp; Hers 品牌运营，提供一个综合数字体验，将用户与持牌医疗服务提供者连接，使其能够进行在线咨询和开处方，涵盖多种健康状况。其远程医疗基础设施支持处方药和非处方产品，并提供送货上门服务。</p>
<p>该公司的产品组合涵盖男性和女性健康的关键领域，包括脱发治疗、性健康疗法、护肤方案和心理健康支持。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们认为比 Hims &amp; Hers Health 更好的股票</li>
<li>HIVE 利用权力进行人工智能转型</li>
<li>深入分析 NVIDIA 最新的投资组合动态</li>
<li>Brady Corp 进行大规模的人工智能驱动突破</li>
<li>为什么 Home Depot 的抛售可能成为一个巨大机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
<p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Hims &amp; Hers Health 并不在名单上。</p>
<p>虽然 Hims &amp; Hers Health 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

HIMS

2 倍做多 HIMS ETF - Defiance

HIMY

标普全球医疗股指数 ETF - iShares

标普医疗保健服务 ETF - SPDR

美国医疗保健供应商 ETF - iShares

医疗业 ETF - Vanguard

<p>美国银行已将 Hims & Hers Health（纽约证券交易所代码：HIMS）的目标价从 30.00 美元下调至 28.00 美元，维持 “中性” 评级。这表明与当前价格相比，仍有 25.44% 的上涨潜力。其他分析师也调整了他们的评级，摩根士丹利设定的目标价为 21.00 美元，花旗集团则将目标价上调至 28.00 美元。Hims & Hers Health 的股票目前交易价格为 22.32 美元</p>

<p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) had its target price reduced by stock analysts at Bank of America from $30.00 to $28.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a &#34;neutral&#34; rating on the stock. Bank of America's price target would suggest a potential upside of 25.44% from the stock's current price.</p>
<div class="lb-trans"><p>Hims  Hers Health（纽约证券交易所代码：HIMS - 获取免费报告）在周二向客户和投资者发布的研究报告中，银行美林的股票分析师将其目标价格从 30.00 美元下调至 28.00 美元。该公司目前对该股票的评级为 “中性”。银行美林的目标价格暗示该股票当前价格有 25.44% 的潜在上涨空间。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Hims  Hers Health</strong> 的提醒：</p>
</div><ul>
<li>Hims &amp; Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims  Hers 股票在第一季度业绩不佳后暴跌：GLP-1 转型是否足以推动复苏？</li>
</ul>
</div><p>Several other equities research analysts have also commented on HIMS. Morgan Stanley cut their price objective on Hims &amp; Hers Health from $40.00 to $21.00 and set an &#34;equal weight&#34; rating for the company in a research report on Tuesday, February 24th. BTIG Research restated a &#34;neutral&#34; rating on shares of Hims &amp; Hers Health in a research report on Tuesday, May 12th. Weiss Ratings downgraded Hims &amp; Hers Health from a &#34;hold (c)&#34; rating to a &#34;sell (d)&#34; rating in a research report on Tuesday, May 12th. Citigroup lifted their price objective on Hims &amp; Hers Health from $24.00 to $28.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, May 12th. Finally, Leerink Partners lifted their price objective on Hims &amp; Hers Health from $17.50 to $25.00 and gave the stock a &#34;market perform&#34; rating in a research report on Monday, March 16th. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Hims &amp; Hers Health currently has an average rating of &#34;Hold&#34; and a consensus price target of $29.37.</p>
<div class="lb-trans"><p>其他几位股票研究分析师也对 HIMS 发表了评论。摩根士丹利将 Hims  Hers Health 的目标价格从 40.00 美元下调至 21.00 美元，并在 2 月 24 日的研究报告中对该公司给予 “等权重” 评级。BTIG Research 在 5 月 12 日的研究报告中重申了对 Hims  Hers Health 股票的 “中性” 评级。Weiss Ratings 在 5 月 12 日的研究报告中将 Hims  Hers Health 的评级从 “持有（c）” 下调至 “卖出（d）”。花旗集团在 5 月 12 日的研究报告中将 Hims  Hers Health 的目标价格从 24.00 美元上调至 28.00 美元，并给予该股票 “中性” 评级。最后，Leerink Partners 在 3 月 16 日的研究报告中将 Hims  Hers Health 的目标价格从 17.50 美元上调至 25.00 美元，并给予该股票 “市场表现” 评级。四位分析师对该股票给予买入评级，十一位给予持有评级，二位给予卖出评级。根据 MarketBeat.com 的数据，Hims  Hers Health 目前的平均评级为 “持有”，共识目标价格为 29.37 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Hims  Hers Health 的最新股票报告</strong></p>
</div><h2>Hims &amp; Hers Health Price Performance</h2>
<div class="lb-trans"><h2>Hims  Hers Health 价格表现</h2>
</div><ul>
<li>Hims &amp; Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims  Hers 财报预览：诺和诺德的转变将 GLP-1 策略置于焦点</li>
</ul>
</div><p>Shares of NYSE:HIMS traded up $0.03 during trading on Tuesday, hitting $22.32. 20,746,443 shares of the stock were exchanged, compared to its average volume of 32,920,871. The company has a fifty day moving average price of $23.92 and a two-hundred day moving average price of $28.60. The company has a market cap of $5.09 billion, a PE ratio of -248.40, a P/E/G ratio of 44.19 and a beta of 2.43. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. Hims &amp; Hers Health has a 12-month low of $13.74 and a 12-month high of $70.43.</p>
<div class="lb-trans"><p>在周二的交易中，NYSE:HIMS 的股票上涨了 0.03 美元，达到 22.32 美元。该股票交易量为 20,746,443 股，而其平均交易量为 32,920,871 股。该公司的 50 日移动平均价格为 23.92 美元，200 日移动平均价格为 28.60 美元。该公司的市值为 50.9 亿美元，市盈率为-248.40，市盈增长比率为 44.19，贝塔值为 2.43。该公司的流动比率为 1.69，速动比率为 1.56，债务与股本比率为 2.18。Hims  Hers Health 的 12 个月低点为 13.74 美元，12 个月高点为 70.43 美元。</p>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The firm had revenue of $608.10 million for the quarter, compared to analysts' expectations of $616.84 million. Hims &amp; Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims &amp; Hers Health's revenue was up 3.8% compared to the same quarter last year. During the same period last year, the firm earned $0.20 EPS. On average, analysts forecast that Hims &amp; Hers Health will post 0.04 EPS for the current year.</p>
<div class="lb-trans"><p>Hims  Hers Health（纽约证券交易所代码：HIMS - 获取免费报告）最后一次公布季度财报是在 5 月 11 日。该公司报告季度每股收益（EPS）为-0.40 美元，低于市场共识预期的 0.04 美元，差距为 0.44 美元。该公司季度收入为 6.081 亿美元，而分析师预期为 6.1684 亿美元。Hims  Hers Health 的股本回报率为 6.10%，净利润率为-0.56%。与去年同期相比，Hims  Hers Health 的收入增长了 3.8%。去年同期，该公司每股收益为 0.20 美元。分析师平均预测 Hims  Hers Health 在当前年度将发布 0.04 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>What the FDA's Latest Proposal Means for Lilly, Novo, and Hims</li>
</ul>
<div class="lb-trans"><ul>
<li>FDA 最新提案对 Lilly、Novo 和 Hims 的影响</li>
</ul>
</div><p>In other news, CFO Oluyemi Okupe sold 36,922 shares of the business's stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80. Following the completion of the sale, the chief financial officer directly owned 281,867 shares of the company's stock, valued at $7,300,355.30. The trade was a 11.58% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 9,463 shares of the business's stock in a transaction on Monday, April 20th. The shares were sold at an average price of $30.00, for a total transaction of $283,890.00. Following the sale, the insider directly owned 299,368 shares of the company's stock, valued at $8,981,040. This represents a 3.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 204,857 shares of company stock valued at $5,285,706. Insiders own 11.76% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席财务官 Oluyemi Okupe 于 4 月 16 日星期四出售了 36,922 股公司的股票。股票以平均价格 25.90 美元出售，总交易额为 956,279.80 美元。出售完成后，首席财务官直接持有 281,867 股公司股票，价值 7,300,355.30 美元。此次交易使其持股减少了 11.58%。该交易在向证券交易委员会的备案中披露，相关信息可在此链接查看。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，内部人士 Soleil Boughton 于 4 月 20 日星期一出售了 9,463 股公司的股票。股票以平均价格 30.00 美元出售，总交易额为 283,890.00 美元。出售后，内部人士直接持有 299,368 股公司股票，价值 8,981,040 美元。这代表其持股减少了 3.06%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去 90 天内，内部人士共出售了 204,857 股公司股票，价值 5,285,706 美元。内部人士持有公司股票的比例为 11.76%。</p>
</div><h2>Institutional Trading of Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>Hims  Hers Health 的机构交易</h2>
</div><p>Several institutional investors have recently made changes to their positions in HIMS. Pathway Capital Management LP purchased a new position in Hims &amp; Hers Health in the 3rd quarter valued at about $6,766,000. Steadview Capital Management LLC raised its stake in Hims &amp; Hers Health by 80.0% during the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company's stock worth $39,809,000 after acquiring an additional 311,845 shares during the period. Farallon Capital Management LLC increased its stake in shares of Hims &amp; Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company's stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period. BIT Capital GmbH increased its stake in shares of Hims &amp; Hers Health by 73.8% in the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company's stock valued at $125,373,000 after purchasing an additional 938,728 shares during the period. Finally, State of Michigan Retirement System increased its stake in shares of Hims &amp; Hers Health by 49.2% in the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company's stock valued at $116,713,000 after purchasing an additional 678,600 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者最近对 HIMS 的持仓进行了调整。Pathway Capital Management LP 在第三季度购买了 Hims  Hers Health 的新头寸，价值约为 6,766,000 美元。Steadview Capital Management LLC 在第三季度将其在 Hims  Hers Health 的持股增加了 80.0%。Steadview Capital Management LLC 目前持有 701,845 股公司股票，价值 39,809,000 美元，此前在该期间内又购买了 311,845 股。Farallon Capital Management LLC 在第三季度将其在 Hims  Hers Health 的持股增加了 30.8%。Farallon Capital Management LLC 目前持有 10,746,852 股公司股票，价值 609,561,000 美元，此前在该期间内又购买了 2,533,271 股。BIT Capital GmbH 在第三季度将其在 Hims  Hers Health 的持股增加了 73.8%。BIT Capital GmbH 目前持有 2,210,384 股公司股票，价值 125,373,000 美元，此前在该期间内又购买了 938,728 股。最后，密歇根州退休系统在第三季度将其在 Hims  Hers Health 的持股增加了 49.2%。密歇根州退休系统目前持有 2,057,700 股公司股票，价值 116,713,000 美元，此前在该期间内又购买了 678,600 股。63.52% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Key Stories Impacting Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>影响 Hims  Hers Health 的关键故事</h2>
</div><p>Here are the key news stories impacting Hims &amp; Hers Health this week:</p>
<div class="lb-trans"><p>以下是本周影响 Hims  Hers Health 的关键新闻故事：</p>
</div><ul>
<li>Negative Sentiment: Hims &amp; Hers announced and then upsized a private offering of 0.00% convertible senior notes due 2032 to $350 million from the originally planned $300 million, raising concerns about future dilution and the balance sheet. Article Title</li>
<li>Neutral Sentiment: The company said the capital will help preserve financial flexibility while funding international expansion, infrastructure, and AI platform investments, which could support longer-term growth. Article Title</li>
<li>Negative Sentiment: Media reports also highlighted investor concern that the move may be tied to the planned Eucalyptus buyout and broader growth initiatives, reinforcing the view that Hims &amp; Hers is leaning on debt to finance expansion. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>消极情绪：Hims &amp; Hers 宣布并扩大了一项 0.00% 可转换高级票据的私人发行，计划到 2032 年到期，金额从原定的 3 亿美元增至 3.5 亿美元，这引发了对未来稀释和资产负债表的担忧。文章标题</li>
<li>中性情绪：该公司表示，这笔资金将有助于保持财务灵活性，同时资助国际扩张、基础设施和人工智能平台投资，这可能支持长期增长。文章标题</li>
<li>消极情绪：媒体报道还强调了投资者的担忧，即此举可能与计划中的 Eucalyptus 收购和更广泛的增长举措有关，进一步强化了 Hims &amp; Hers 借债融资扩张的观点。文章标题</li>
</ul>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>关于 Hims &amp; Hers Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Hims &amp; Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims &amp; Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc 是一个远程医疗平台，提供直接面向消费者的个人护理产品和虚拟医疗服务，服务于美国市场。该公司以 Hims &amp; Hers 品牌运营，提供一个综合数字体验，将用户与持牌医疗服务提供者连接，使其能够进行在线咨询和开处方，涵盖多种健康状况。其远程医疗基础设施支持处方药和非处方产品，并提供送货上门服务。</p>
</div><p>The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.</p>
<div class="lb-trans"><p>该公司的产品组合涵盖男性和女性健康的关键领域，包括脱发治疗、性健康疗法、护肤方案和心理健康支持。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>HIVE Weaponizes Power for an AI Pivot</li>
<li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li>
<li>Brady Corp Wires Up a Massive AI-Powered Breakout</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Hims &amp; Hers Health 更好的股票</li>
<li>HIVE 利用权力进行人工智能转型</li>
<li>深入分析 NVIDIA 最新的投资组合动态</li>
<li>Brady Corp 进行大规模的人工智能驱动突破</li>
<li>为什么 Home Depot 的抛售可能成为一个巨大机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Hims &amp; Hers Health 吗？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Hims &amp; Hers Health 并不在名单上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Hims &amp; Hers Health 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Bank of America Lowers Hims & Hers Health (NYSE:HIMS) Price Target to $28.00

Market Beat

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

美国银行

摩根士丹利

花旗

诺和诺德公司

礼来

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

美国银行将 Hims & Hers Health（NYSE:HIMS）的目标股价下调至 28.00 美元